Quantile Effect on Duration of Response: A Zero‐Inflated Censored Regression Approach

Duration of response (DOR) has been increasingly used as a useful measure of response to treatments in randomized clinical trials (RCT). Some estimands for DOR, such as the restricted mean DOR, although simple to use, may be sensitive to outliers and may not correctly measure treatment effects on the quantiles of DOR, such as the proportion of patients with DOR of at least 3 months. Quantile regression for survival data has been well developed. However, it is not directly applicable to DOR data in RCTs, due to the presence of non-responders for whom DOR is not defined. Although they can be treated as having zero DOR in a standard quantile regression, such an approach may not be flexible to model these subset of patients. To mitigate this issue, we propose an approach similar to the two-parts zero-inflated models, for example, for count data, so that the nonresponders are modeled as a part of the model, while DOR is modeled using quantile regression. A simulation study is conducted to examine the performance of the proposed approach. For illustration, we apply our approach to a simulated dataset of an acute myeloid leukemia trial, since the true dataset cannot be used due to confidentiality. The asymptotic properties of the proposed approach are also derived.

Authors

Institutions

Publication Details

Journal
Pharmaceutical Statistics
Published
2025-11-01
DOI
https://doi.org/10.1002/pst.70053
Primary Topic
Statistical Methods and Inference
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quantile Effect on Duration of Response: A Zero‐Inflated Censored Regression Approach

Ram C. Tiwari, Jixian Wang, Nan Sun
Pharmaceutical Statistics
Statistical Methods and Inference
article

Quantile Effect on Duration of Response: A Zero‐Inflated Censored Regression Approach

Ram C. Tiwari, Jixian Wang, Nan Sun
article en

Abstract

Duration of response (DOR) has been increasingly used as a useful measure of response to treatments in randomized clinical trials (RCT). Some estimands for DOR, such as the restricted mean DOR, although simple to use, may be sensitive to outliers and may not correctly measure treatment effects on the quantiles of DOR, such as the proportion of patients with DOR of at least 3 months. Quantile regression for survival data has been well developed. However, it is not directly applicable to DOR data in RCTs, due to the presence of non-responders for whom DOR is not defined. Although they can be treated as having zero DOR in a standard quantile regression, such an approach may not be flexible to model these subset of patients. To mitigate this issue, we propose an approach similar to the two-parts zero-inflated models, for example, for count data, so that the nonresponders are modeled as a part of the model, while DOR is modeled using quantile regression. A simulation study is conducted to examine the performance of the proposed approach. For illustration, we apply our approach to a simulated dataset of an acute myeloid leukemia trial, since the true dataset cannot be used due to confidentiality. The asymptotic properties of the proposed approach are also derived.

Pharmaceutical StatisticsVol. 24(6)
Danone (China) (CN), CorSolutions (United States) (US), Bristol-Myers Squibb (Switzerland) (CH)
Openalex Percentile: Top 67%
Statistical Methods and Inference
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.